

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ENNUMO safely and effectively. See [full prescribing information](#) for ENNUMO.

ENNUMO™ (pegfilgrastim-pccg) injection, for subcutaneous use
Initial U.S. Approval: 2026

ENNUMO (pegfilgrastim-pccg) is biosimilar* to NEULASTA® (pegfilgrastim).

INDICATIONS AND USAGE

ENNUMO is a leukocyte growth factor indicated in adults and pediatric patients aged newborn and older to:

- Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1.1)
- Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (1.2)

Limitations of Use

ENNUMO is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

DOSAGE AND ADMINISTRATION

- Patients with cancer receiving myelosuppressive chemotherapy
 - For adult patients of any weight and pediatric patients weighing 45 kg and greater, the recommended dosage is 6 mg subcutaneously once per chemotherapy cycle. (2.1)
 - Do not administer between 14 days before and 24 hours after administration of chemotherapy. (2.1)
- Patients acutely exposed to myelosuppressive doses of radiation
 - For adults of any weight and pediatric patients weighing 45 kg and greater, the recommended dosage is two doses, 6 mg each, subcutaneously one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation, and a second dose one week after. (2.2)

DOSAGE FORMS AND STRENGTHS

Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual use only. (3)

CONTRAINDICATIONS

In patients with a history of serious hypersensitivity reaction to pegfilgrastim

products or filgrastim products. (4)

WARNINGS AND PRECAUTIONS

- Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. (5.1)
- Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue ENNUMO in patients with ARDS. (5.2)
- Serious hypersensitivity reactions, including anaphylaxis: Permanently discontinue ENNUMO in patients with serious hypersensitivity reactions. (5.3)
- Fatal sickle cell crises: Discontinue ENNUMO if sickle cell crisis occurs. (5.4)
- Glomerulonephritis: Evaluate and consider dose-reduction or interruption of ENNUMO if causality is likely. (5.5)
- Thrombocytopenia: Monitor platelet counts. (5.7)
- Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Monitor patients with breast and lung cancer using ENNUMO in conjunction with chemotherapy and/or radiotherapy for signs and symptoms of MDS/AML. (5.10)
- Aortitis: Discontinue ENNUMO if aortitis is suspected. (5.11)

ADVERSE REACTIONS

Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Accord BioPharma Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ENNUMO has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

Revised: 05/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE	5.12 Nuclear Imaging
1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy	6 ADVERSE REACTIONS
1.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome	6.1 Clinical Trials Experience
2 DOSAGE AND ADMINISTRATION	6.2 Postmarketing Experience
2.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy	8 USE IN SPECIFIC POPULATIONS
2.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome	8.1 Pregnancy
2.3 Preparation and Administration	8.2 Lactation
3 DOSAGE FORMS AND STRENGTHS	8.4 Pediatric Use
4 CONTRAINDICATIONS	8.5 Geriatric Use
5 WARNINGS AND PRECAUTIONS	10 OVERDOSAGE
5.1 Splenic Rupture	11 DESCRIPTION
5.2 Acute Respiratory Distress Syndrome	12 CLINICAL PHARMACOLOGY
5.3 Serious Hypersensitivity Reactions	12.1 Mechanism of Action
5.4 Use in Patients with Sickle Cell Disorders	12.2 Pharmacodynamics
5.5 Glomerulonephritis	12.3 Pharmacokinetics
5.6 Leukocytosis	12.6 Immunogenicity
5.7 Thrombocytopenia	13 NONCLINICAL TOXICOLOGY
5.8 Capillary Leak Syndrome	13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
5.9 Potential for Tumor Growth Stimulatory Effects on Malignant Cells	14 CLINICAL STUDIES
5.10 Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer	14.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy
5.11 Aortitis	14.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome
	16 HOW SUPPLIED/STORAGE AND HANDLING
	17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy

ENNUMO is indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see *Clinical Studies (14.1)*].

Limitations of Use

ENNUMO is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

1.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome

ENNUMO is indicated to increase survival in adults and pediatric patients aged newborn and older acutely exposed to myelosuppressive doses of radiation [see *Dosage and Administration (2.2)* and *Clinical Studies (14.2)*].

2 DOSAGE AND ADMINISTRATION

2.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy

The recommended dosage of ENNUMO for adults of any weight and pediatric patients weighing at least 45 kg with cancer receiving myelosuppressive chemotherapy is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle. Do not administer ENNUMO between 14 days before and 24 hours after administration of chemotherapy.

2.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome

The recommended dosage of ENNUMO for adults of any weight and pediatric patients weighing at least 45 kg with hematopoietic subsyndrome of acute radiation syndrome is two doses, 6 mg each, administered subcutaneously one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to radiation levels greater than 2 gray (Gy). Administer the second dose one week after the first dose.

Obtain a baseline complete blood count (CBC). Do not delay administration of ENNUMO if a CBC is not readily available. Estimate a patient's absorbed radiation dose (i.e., level of radiation exposure) based on information from public health authorities, biodosimetry if available, or clinical findings such as time to onset of vomiting or lymphocyte depletion kinetics.

2.3 Preparation and Administration

ENNUMO is supplied in single-dose prefilled syringes for manual use [see *Dosage Forms and Strengths (3)*].

Before using ENNUMO prefilled syringe:

- Remove the carton from the refrigerator and allow the ENNUMO prefilled syringe to reach room temperature, 20°C to 25°C (68°F to 77°F), for a minimum of 30 minutes. Do not warm in any other way. Discard any prefilled syringe left at room temperature for greater than 48 hours.
- ENNUMO is a clear, colorless, preservative-free solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer ENNUMO if discoloration or particulates are observed.

Prefilled Syringe for Manual Use

For adult patients of any weight and pediatric patients weighing 45 kg and greater, the single-dose prefilled syringe for manual use is intended for subcutaneous administration of a single 6 mg/0.6 mL dose of ENNUMO. The syringe does not bear graduation marks and therefore does not allow for direct administration of doses less than 6 mg/0.6 mL. There is no presentation for ENNUMO that allows weight-based dosing for pediatric patients below 45 kg.

The needle cap on the prefilled syringes contains dry natural rubber (derived from latex); persons with latex allergies should not administer these products.

3 DOSAGE FORMS AND STRENGTHS

ENNUMO is a clear, colorless, preservative-free solution available as:

- Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.

4 CONTRAINDICATIONS

ENNUMO is contraindicated in patients with a history of a serious hypersensitivity reaction to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis [*see Warnings and Precautions (5.3)*].

5 WARNINGS AND PRECAUTIONS

5.1 Splenic Rupture

Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving ENNUMO.

5.2 Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome (ARDS) can occur in patients receiving pegfilgrastim products. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving ENNUMO, for ARDS. Discontinue ENNUMO in patients with ARDS.

5.3 Serious Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products. The majority of reported events occurred upon initial exposure. Hypersensitivity reactions, including anaphylaxis, can recur within days after the discontinuation of initial therapies to manage the reaction. Permanently discontinue ENNUMO in patients with serious hypersensitivity reactions. ENNUMO is contraindicated in patients with a history of a serious hypersensitivity reaction to pegfilgrastim products or filgrastim products.

5.4 Use in Patients with Sickle Cell Disorders

Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products. Discontinue ENNUMO if sickle cell crisis occurs.

5.5 Glomerulonephritis

Glomerulonephritis has occurred in patients receiving pegfilgrastim products. The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of pegfilgrastim products. If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of ENNUMO.

5.6 Leukocytosis

White blood cell (WBC) counts of $100 \times 10^9/L$ or greater have been observed in patients receiving pegfilgrastim products. Monitoring of complete blood count (CBC) during ENNUMO therapy is recommended.

5.7 Thrombocytopenia

Pegfilgrastim products can cause thrombocytopenia. Monitor platelet counts during ENNUMO therapy.

5.8 Capillary Leak Syndrome

Capillary leak syndrome has been reported after G-CSF administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.

5.9 Potential for Tumor Growth Stimulatory Effects on Malignant Cells

The granulocyte colony-stimulating factor (G-CSF) receptor through which pegfilgrastim products and filgrastim products act has been found on tumor cell lines. The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded.

5.10 Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer

MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.

5.11 Aortitis

Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count). Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue ENNUMO if aortitis is suspected.

5.12 Nuclear Imaging

Increased hematopoietic activity of the bone marrow in response to growth factor therapy, including pegfilgrastim products, has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:

- Splenic Rupture *[see Warnings and Precautions (5.1)]*
- Acute Respiratory Distress Syndrome *[see Warnings and Precautions (5.2)]*
- Serious Hypersensitivity Reactions *[see Warnings and Precautions (5.3)]*
- Use in Patients with Sickle Cell Disorders *[see Warnings and Precautions (5.4)]*
- Glomerulonephritis *[see Warnings and Precautions (5.5)]*
- Leukocytosis *[see Warnings and Precautions (5.6)]*
- Thrombocytopenia *[see Warnings and Precautions (5.7)]*
- Capillary Leak Syndrome *[see Warnings and Precautions (5.8)]*
- Potential for Tumor Growth Stimulatory Effects on Malignant Cells *[see Warnings and Precautions (5.9)]*
- Myelodysplastic Syndrome *[see Warnings and Precautions (5.10)]*
- Acute myeloid leukemia *[see Warnings and Precautions (5.10)]*
- Aortitis *[see Warnings and Precautions (5.11)]*

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Pegfilgrastim clinical trials safety data are based upon 932 patients receiving pegfilgrastim in seven randomized clinical trials. The population was 21 to 88 years of age and 92% female. The ethnicity was 75% Caucasian, 18% Hispanic, 5% Black, and 1% Asian. Patients with breast (n = 823), lung and thoracic tumors (n = 53) and lymphoma (n = 56) received pegfilgrastim after nonmyeloablative cytotoxic chemotherapy. Most patients received a single 100 mcg/kg (n = 259) or a single 6 mg (n = 546) dose per chemotherapy cycle over 4 cycles.

The following adverse reaction data in Table 1 are from a randomized, double-blind, placebo-controlled study in

patients with metastatic or non-metastatic breast cancer receiving docetaxel 100 mg/m² every 21 days (Study 3). A total of 928 patients were randomized to receive either 6 mg pegfilgrastim (n = 467) or placebo (n = 461). The patients were 21 to 88 years of age and 99% female. The ethnicity was 66% Caucasian, 31% Hispanic, 2% Black, and < 1% Asian, Native American, or other.

The most common adverse reactions occurring in ≥ 5% of patients and with a between-group difference of ≥ 5% higher in the pegfilgrastim arm in placebo-controlled clinical trials are bone pain and pain in extremity.

Table 1. Adverse Reactions with ≥ 5% Higher Incidence in Pegfilgrastim Patients Compared to Placebo in Study 3

Body System Adverse Reaction	Placebo (N = 461)	Pegfilgrastim 6 mg SC on Day 2 (N = 467)
Musculoskeletal and connective tissue disorders		
Bone pain	26%	31%
Pain in extremity	4%	9%

Leukocytosis

In clinical studies, leukocytosis (WBC counts > 100 x 10⁹/L) was observed in less than 1% of 932 patients with non-myeloid malignancies receiving pegfilgrastim. No complications attributable to leukocytosis were reported in clinical studies.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of pegfilgrastim products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- Splenic rupture and splenomegaly (enlarged spleen) [see *Warnings and Precautions* (5.1)]
- Acute respiratory distress syndrome (ARDS) [see *Warnings and Precautions* (5.2)]
- Allergic reactions/hypersensitivity, including anaphylaxis, skin rash, urticaria, generalized erythema, and flushing [see *Warnings and Precautions* (5.3)]
- Sick cell crisis [see *Warnings and Precautions* (5.4)]
- Glomerulonephritis [see *Warnings and Precautions* (5.5)]
- Leukocytosis [see *Warnings and Precautions* (5.6)]
- Thrombocytopenia [see *Warnings and Precautions* (5.7)]
- Capillary Leak Syndrome [see *Warnings and Precautions* (5.8)]
- Injection site reactions
- Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis
- Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy [see *Warnings and Precautions* (5.10)]
- Aortitis [see *Warnings and Precautions* (5.11)]
- Alveolar hemorrhage

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Although available data with pegfilgrastim product use in pregnant women are insufficient to establish whether there is a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, there are available data from published studies in pregnant women exposed to filgrastim products. These studies have not established an association of filgrastim product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes.

In animal studies, no evidence of reproductive/developmental toxicity occurred in the offspring of pregnant rats that received cumulative doses of pegfilgrastim approximately 10 times the recommended human dose (based on body surface area). In pregnant rabbits, increased embryoletality and spontaneous abortions occurred at 4 times the maximum recommended human dose simultaneously with signs of maternal toxicity (*see Data*).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

Pregnant rabbits were dosed with pegfilgrastim subcutaneously every other day during the period of organogenesis. At cumulative doses ranging from the approximate human dose to approximately 4 times the recommended human dose (based on body surface area), the treated rabbits exhibited decreased maternal food consumption, maternal weight loss, as well as reduced fetal body weights and delayed ossification of the fetal skull; however, no structural anomalies were observed in the offspring from either study. Increased incidences of post-implantation losses and spontaneous abortions (more than half the pregnancies) were observed at cumulative doses approximately 4 times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose.

Three studies were conducted in pregnant rats dosed with pegfilgrastim at cumulative doses up to approximately 10 times the recommended human dose at the following stages of gestation: during the period of organogenesis, from mating through the first half of pregnancy, and from the first trimester through delivery and lactation. No evidence of fetal loss or structural malformations was observed in any study. Cumulative doses equivalent to approximately 3 and 10 times the recommended human dose resulted in transient evidence of wavy ribs in fetuses of treated mothers (detected at the end of gestation but no longer present in pups evaluated at the end of lactation).

8.2 Lactation

Risk Summary

There are no data on the presence of pegfilgrastim products in human milk, the effects on the breastfed child, or the effects on milk production. Other filgrastim products are secreted poorly into breast milk, and filgrastim products are not absorbed orally by neonates. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ENNUMO and any potential adverse effects on the breastfed child from ENNUMO or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of ENNUMO for chemotherapy-induced neutropenia and hematopoietic subsyndrome of acute radiation syndrome have been established in pediatric patients aged newborn and older.

Use of ENNUMO in pediatric patients for chemotherapy-induced neutropenia is based on adequate and well-controlled studies of pegfilgrastim in adults with additional pharmacokinetic and safety data of pegfilgrastim in pediatric patients aged 8 months and older with sarcoma [*see Clinical Pharmacology (12.3) and Clinical Studies (14.1)*].

The use of ENNUMO to increase survival in pediatric patients acutely exposed to myelosuppressive doses of radiation is based on efficacy studies of pegfilgrastim conducted in animals and clinical data supporting the use of pegfilgrastim in patients with cancer receiving myelosuppressive chemotherapy. Efficacy studies of pegfilgrastim products could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Results from population modeling and simulation indicate that two doses of pegfilgrastim, administered one week apart provide pediatric patients with exposures comparable to that in adults receiving two 6 mg doses one week apart [*see Dosage and Administration (2.1, 2.2), Clinical Pharmacology (12.3) and Clinical Studies (14.2)*].

8.5 Geriatric Use

Of the 932 patients with cancer who received pegfilgrastim in clinical studies, 139 (15%) were aged 65 and over, and 18 (2%) were aged 75 and over. No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients.

10 OVERDOSAGE

Overdosage of pegfilgrastim products may result in leukocytosis and bone pain. Events of edema, dyspnea, and pleural effusion have been reported in a single patient who administered pegfilgrastim on 8 consecutive days in error. In the event of overdose, the patient should be monitored for adverse reactions [see *Adverse Reactions (6)*]. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

11 DESCRIPTION

Pegfilgrastim-pccg is a covalent conjugate of recombinant methionyl human G-CSF and monomethoxypolyethylene glycol. Recombinant methionyl human G-CSF is a water-soluble 175 amino acid protein with a molecular weight of approximately 19 kilodaltons (kD). Recombinant methionyl human G-CSF is obtained from the bacterial fermentation of a strain of *E coli* transformed with a genetically engineered plasmid containing the human G-CSF gene. To produce pegfilgrastim-pccg, a 20 kD monomethoxypolyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of recombinant methionyl human G-CSF. The average molecular weight of pegfilgrastim-pccg is approximately 39 kD.

ENNUMO (pegfilgrastim-pccg) injection is a sterile, clear, colorless, preservative-free solution with a pH of 4.0, supplied in single-dose prefilled syringes for manual subcutaneous injection.

Prefilled Syringe for Manual Use

- The prefilled syringe does not bear graduation marks and is designed to deliver the entire contents of the syringe (6 mg/0.6 mL).

The delivered 0.6 mL dose from the ENNUMO prefilled syringe for manual subcutaneous injection contains 6 mg pegfilgrastim-pccg (based on protein weight), glacial acetic acid (0.35 mg), polysorbate 20 (0.02 mg), sodium hydroxide (0.034 mg), and sorbitol (30 mg) in Water for Injection, USP.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.

12.2 Pharmacodynamics

Animal data and clinical data in humans suggest a correlation between pegfilgrastim products' exposure and the duration of severe neutropenia as a predictor of efficacy. Selection of the dosing regimen of ENNUMO is based on reducing the duration of severe neutropenia.

12.3 Pharmacokinetics

The pharmacokinetics of pegfilgrastim was studied in 379 patients with cancer. The pharmacokinetics of pegfilgrastim was nonlinear, and clearance decreased with increases in dose. Neutrophil receptor binding is an important component of the clearance of pegfilgrastim, and serum clearance is directly related to the number of neutrophils. In addition to numbers of neutrophils, body weight appeared to be a factor. Patients with higher body weights experienced higher systemic exposure to pegfilgrastim after receiving a dose normalized for body weight. A large variability in the pharmacokinetics of pegfilgrastim was observed. The half-life of pegfilgrastim ranged from 15 to 80 hours after subcutaneous injection.

Specific Populations

No gender-related differences were observed in the pharmacokinetics of pegfilgrastim, and no differences were observed in the pharmacokinetics of geriatric patients (≥ 65 years of age) compared with younger patients (< 65 years of age) [see *Use in Specific Populations (8.5)*].

Renal Impairment

In a study of 30 subjects with varying degrees of renal dysfunction, including end stage renal disease, renal dysfunction

had no effect on the pharmacokinetics of pegfilgrastim.

Pediatric Patients with Cancer Receiving Myelosuppressive Chemotherapy

The pharmacokinetics and safety of pegfilgrastim were studied in 37 pediatric patients with sarcoma in Study 4 [see *Clinical Studies 14.1*]. The mean ($\pm$ standard deviation [SD]) systemic exposure ($AUC_{0-\infty}$) of pegfilgrastim after subcutaneous administration at 100 mcg/kg was 47.9 ($\pm$ 22.5) mcg·hr/mL in the youngest age group (0 to 5 years, n = 11), 22.0 ($\pm$ 13.1) mcg·hr/mL in the 6 to 11 years age group (n=10), and 29.3 ($\pm$ 23.2) mcg·hr/mL in the 12 to 21 years age group (n = 13). The terminal elimination half-lives of the corresponding age groups were 30.1 ($\pm$ 38.2) hours, 20.2 ($\pm$ 11.3) hours, and 21.2 ($\pm$ 16.0) hours, respectively.

Patients Acutely Exposed to Myelosuppressive Doses of Radiation

The pharmacokinetics of pegfilgrastim products is not available in patients acutely exposed to myelosuppressive doses of radiation. Based on limited pharmacokinetic data in irradiated non-human primates, the area under the concentration-time curve (AUC), reflecting the exposure to pegfilgrastim in non-human primates following a 300 mcg/kg dose of pegfilgrastim, appears to be greater than in humans receiving a 6 mg dose. Results from population modeling and simulation indicate that two 6 mg doses of pegfilgrastim administered one week apart in adults result in clinically relevant effects on duration of grade 3 and 4 neutropenia. In addition, weight based dosing in pediatric patients weighing less than 45 kg provides exposures comparable to those in adults receiving two 6 mg doses one week apart.

12.6 Immunogenicity

The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of pegfilgrastim or of other pegfilgrastim products.

Binding antibodies to pegfilgrastim were detected using a BIAcore assay. The approximate limit of detection for this assay is 500 ng/mL. Pre-existing binding antibodies were detected in approximately 6% (51/849) of patients with metastatic breast cancer. Four of 521 pegfilgrastim-treated subjects who were negative at baseline developed binding antibodies to pegfilgrastim following treatment. None of these 4 patients had evidence of neutralizing antibodies detected using a cell-based bioassay.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No carcinogenicity or mutagenesis studies have been performed with pegfilgrastim products.

Pegfilgrastim did not affect reproductive performance or fertility in male or female rats at cumulative weekly doses approximately 6 to 9 times higher than the recommended human dose (based on body surface area).

14 CLINICAL STUDIES

14.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy

Pegfilgrastim was evaluated in three randomized, double-blind, controlled studies. Studies 1 and 2 were active-controlled studies that employed doxorubicin 60 mg/m² and docetaxel 75 mg/m² administered every 21 days for up to 4 cycles for the treatment of metastatic breast cancer. Study 1 investigated the utility of a fixed dose of pegfilgrastim. Study 2 employed a weight-adjusted dose. In the absence of growth factor support, similar chemotherapy regimens have been reported to result in a 100% incidence of severe neutropenia ($ANC < 0.5 \times 10^9/L$) with a mean duration of 5 to 7 days and a 30% to 40% incidence of febrile neutropenia. Based on the correlation between the duration of severe neutropenia and the incidence of febrile neutropenia found in studies with filgrastim, duration of severe neutropenia was chosen as the primary endpoint in both studies, and the efficacy of pegfilgrastim was demonstrated by establishing comparability to filgrastim-treated patients in the mean days of severe neutropenia.

In Study 1, 157 patients were randomized to receive a single subcutaneous injection of pegfilgrastim (6 mg) on day 2 of each chemotherapy cycle or daily subcutaneous filgrastim (5 mcg/kg/day) beginning on day 2 of each chemotherapy cycle. In Study 2, 310 patients were randomized to receive a single subcutaneous injection of pegfilgrastim (100 mcg/kg) on day 2 or daily subcutaneous filgrastim (5 mcg/kg/day) beginning on day 2 of each chemotherapy cycle.

Both studies met the major efficacy outcome measure of demonstrating that the mean days of severe neutropenia of

pegfilgrastim-treated patients did not exceed that of filgrastim-treated patients by more than 1 day in cycle 1 of chemotherapy. The mean days of cycle 1 severe neutropenia in Study 1 were 1.8 days in the pegfilgrastim arm compared to 1.6 days in the filgrastim arm [difference in means 0.2 (95% CI - 0.2, 0.6)] and in Study 2 were 1.7 days in the pegfilgrastim arm compared to 1.6 days in the filgrastim arm [difference in means 0.1 (95% CI - 0.2, 0.4)].

A secondary endpoint in both studies was days of severe neutropenia in cycles 2 through 4 with results similar to those for cycle 1.

Study 3 was a randomized, double-blind, placebo-controlled study that employed docetaxel 100 mg/m² administered every 21 days for up to 4 cycles for the treatment of metastatic or non-metastatic breast cancer. In this study, 928 patients were randomized to receive a single subcutaneous injection of pegfilgrastim (6 mg) or placebo on day 2 of each chemotherapy cycle. Study 3 met the major trial outcome measure of demonstrating that the incidence of febrile neutropenia (defined as temperature $\geq 38.2^{\circ}\text{C}$ and ANC $\leq 0.5 \times 10^9/\text{L}$) was lower for pegfilgrastim-treated patients as compared to placebo-treated patients (1% versus 17%, respectively, $p < 0.001$). The incidence of hospitalizations (1% versus 14%) and IV anti-infective use (2% versus 10%) for the treatment of febrile neutropenia was also lower in the pegfilgrastim-treated patients compared to the placebo-treated patients.

Study 4 was a multicenter, randomized, open-label study to evaluate the efficacy, safety, and pharmacokinetics [see *Clinical Pharmacology* (12.3)] of pegfilgrastim in pediatric and young adult patients with sarcoma. Patients with sarcoma receiving chemotherapy age 0 to 21 years were eligible. Patients were randomized to receive subcutaneous pegfilgrastim as a single-dose of 100 mcg/kg ($n = 37$) or subcutaneous filgrastim at a dose 5 mcg/kg/day ($n = 6$) following myelosuppressive chemotherapy. Recovery of neutrophil counts was similar in the pegfilgrastim and filgrastim groups. The most common adverse reaction reported was bone pain.

14.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome

Efficacy studies of pegfilgrastim products could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Approval of this indication was based on efficacy studies conducted in animals and data supporting pegfilgrastim's effect on severe neutropenia in patients with cancer receiving myelosuppressive chemotherapy [see *Dosage and Administration* (2.1)].

The recommended dose of ENNUMO is two doses, 6 mg each, administered one week apart for humans exposed to myelosuppressive doses of radiation. For pediatric patients weighing less than 45 kg, dosing of ENNUMO is weight based. This dosing regimen is based on population modeling and simulation analyses. The exposure associated with this dosing regimen is expected to provide sufficient pharmacodynamic activity to treat humans exposed to myelosuppressive doses of radiation [see *Clinical Pharmacology* (12.3)]. The safety of pegfilgrastim at a dose of 6 mg has been assessed on the basis of clinical experience in patients with cancer receiving myelosuppressive chemotherapy.

The efficacy of pegfilgrastim for the acute radiation syndrome setting was studied in a randomized, placebo-controlled non-human primate model of radiation injury. Rhesus macaques were randomized to either a control ($n = 23$) or treated ($n = 23$) cohort. On study day 0, animals ($n = 6$ to 8 per irradiation day) were exposed to total body irradiation (TBI) of 7.50 ± 0.15 Gy delivered at 0.8 ± 0.03 Gy/min, representing a dose that would be lethal in 50% of animals by 60 days of follow-up (LD50/60). Animals were administered subcutaneous injections of a blinded treatment (control article [5% dextrose in water] or pegfilgrastim [300-319 mcg/kg/day]) on study day 1 and on study day 8. The primary endpoint was survival. Animals received medical management consisting of intravenous fluids, antibiotics, blood transfusions, and other support as required.

Pegfilgrastim significantly (at 0.0014 level of significance) increased 60-day survival in irradiated non-human primates: 91% survival (21/23) in the pegfilgrastim group compared to 48% survival (11/23) in the control group.

16 HOW SUPPLIED/STORAGE AND HANDLING

ENNUMO single-dose prefilled syringe for manual use

ENNUMO (pegfilgrastim-pccg) injection is a clear, colorless solution supplied in a prefilled single-dose syringe for manual use containing 6 mg pegfilgrastim-pccg, supplied with a 27-gauge, 1/2-inch needle with an UltraSafe PassiveTM Needle Guard.

The needle cap of the prefilled syringe contains dry natural rubber (a derivative of latex).

ENNUMO is provided in a carton containing one sterile 6 mg/0.6 mL prefilled syringe (NDC 69448-012-63).

ENNUMO prefilled syringe does not bear graduation marks and is intended only to deliver the entire contents of the syringe (6 mg/0.6 mL) for direct administration.

Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Discard syringes stored at room temperature for more than 48 hours. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard syringe if frozen more than once. Do not shake.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Advise patients of the following risks and potential risks with ENNUMO:

- Splenic rupture and splenomegaly
- Acute Respiratory Distress Syndrome
- Serious hypersensitivity reactions
- Sickle cell crisis
- Glomerulonephritis
- Increased risk of Myelodysplastic Syndrome and/or Acute Myeloid Leukemia in patients with breast and lung cancer who receive ENNUMO in conjunction with chemotherapy and /or radiation therapy
- Capillary Leak Syndrome
- Aortitis

Advise patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome) that efficacy studies of pegfilgrastim products for this indication could not be conducted in humans for ethical and feasibility reasons and that, therefore, approval of this use was based on efficacy studies conducted in animals [see *Clinical Studies (14.2)*].

Instruct patients who self-administer ENNUMO using the single-dose prefilled syringe of the:

- Importance of following the Instructions for Use.
- Dangers of reusing syringes.
- Importance of following local requirements for proper disposal of used syringes.



Manufactured by:

Accord BioPharma Inc.
8041 Arco Corporate Drive, Suite 200,
Raleigh, NC 27617 USA

US License No.: 2105

Manufactured at:

Intas Pharmaceuticals Limited
Plot no: 423/P/A, Sarkhej-Bavla Highway,
Moraiya, Ahmedabad, Gujarat 382213, India

UltraSafe Passive™ Needle Guard is a trademark of Becton, Dickinson and Company.

Patient Information
ENNUMO™ (eh-noo-moe)
(pegfilgrastim-pccg)
injection
Single-Dose Prefilled Syringe

What is ENNUMO?

ENNUMO is a prescription medicine that is used:

- in adults and children aged newborn and older to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid), who receive anti-cancer medicines (chemotherapy) that can cause fever and low blood cell count.
- in adults and children aged newborn and older for acute radiation syndrome. The effectiveness of pegfilgrastim for this use was only studied in animals, because it could not be studied in people.

Do not take ENNUMO if you have had a serious allergic reaction to pegfilgrastim products or filgrastim products.

Before you receive ENNUMO, tell your healthcare provider about all of your medical conditions, including if you:

- have a sickle cell disorder.
- have kidney problems.
- are allergic to latex. The needle cap on the prefilled syringe contains dry natural rubber (derived from latex). You should not give ENNUMO using the prefilled syringe if you have latex allergies.
- are pregnant or plan to become pregnant. It is not known if ENNUMO will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if ENNUMO passes into your breast milk.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive ENNUMO?

- **ENNUMO is given as an injection under your skin (subcutaneous injection) by a healthcare provider. If your healthcare provider decides that the subcutaneous injections can be given at home by you or your caregiver, follow the detailed “Instructions for Use” that comes with your ENNUMO for information on how to prepare and inject a dose of ENNUMO using the single-dose prefilled syringe.**
- You and your caregiver will be shown how to prepare and inject ENNUMO using the single-dose prefilled syringe before you use it.
- You should not inject a dose of ENNUMO to children weighing less than 99 pounds (45 kg) from an ENNUMO prefilled syringe.
- If you are receiving ENNUMO because you are also receiving chemotherapy, the last dose of ENNUMO should be injected at least 14 days before and 24 hours after your dose of chemotherapy.
- If you miss a dose of ENNUMO, talk to your healthcare provider about when you should give your next dose.
- If you inject too much ENNUMO, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

What are possible side effects of ENNUMO?

ENNUMO may cause serious side effects, including:

- **Spleen rupture.** Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder.
- **A serious lung problem called Acute Respiratory Distress Syndrome (ARDS).** Call your healthcare provider or get emergency help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.
- **Serious allergic reactions.** Allergic reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using ENNUMO and call your healthcare provider or get emergency medical help right away.
- **Sickle cell crises in people with sickle cell disorder.** You may have a severe sickle cell crisis, which could lead to death. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.
- **Kidney injury.** Call your healthcare provider right away if you develop any of the following symptoms:
 - swelling of your face or ankles

- blood in your urine or dark colored urine
- you urinate less than usual
- **Increased white blood cell count (leukocytosis).** Your healthcare provider will check your blood count during treatment with ENNUMO.
- **Decreased platelet count (thrombocytopenia).** Your healthcare provider will check your blood count during treatment with ENNUMO. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with ENNUMO.
- **Capillary Leak Syndrome (CLS).** ENNUMO can cause fluid to leak from blood vessels into your body's tissues. CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
 - swelling or puffiness and are urinating less than usual
 - trouble breathing
 - swelling of your stomach area (abdomen) and feeling of fullness
 - dizziness or feeling faint
 - a general feeling of tiredness
- **Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML).** If you have breast cancer or lung cancer, when ENNUMO is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called MDS or a blood cancer called AML. Call your healthcare provider if you develop any symptoms of MDS and AML, including tiredness, fever, or easy bruising or bleeding.
- **Inflammation of the aorta (aortitis).** Inflammation of the aorta (the large blood vessel that carries blood from the heart to the body) has happened in people who receive pegfilgrastim products. Tell your healthcare provider if you develop fever, stomach (abdominal) pain, feeling tired, or back pain.

The most common side effects of ENNUMO are pain in the bones, arms, and legs.

These are not all the possible side effects of ENNUMO.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store ENNUMO single-dose prefilled syringes?

- Store ENNUMO in the refrigerator between 36°F to 46°F (2°C to 8°C).
- Avoid freezing. If ENNUMO is accidentally frozen, allow the prefilled syringe to thaw in the refrigerator before injecting.
- **Do not** use an ENNUMO prefilled syringe that has been frozen more than 1 time. Throw it away and use a new ENNUMO prefilled syringe.
- Keep ENNUMO in the original carton to protect from light or physical damage.
- Do not shake ENNUMO.
- Take ENNUMO out of the refrigerator 30 minutes before use and allow it to reach room temperature, 68°F to 77°F (20°C to 25°C), before preparing an injection.
- Throw away (dispose of) any ENNUMO that has been left at room temperature, 68°F to 77°F (20°C to 25°C), for more than 48 hours.

Keep ENNUMO and all medicines out of the reach of children.

General information about the safe and effective use of ENNUMO.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ENNUMO for a condition for which it was not prescribed. Do not give ENNUMO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ENNUMO that is written for health professionals.

What are the ingredients in ENNUMO?

Active ingredient: pegfilgrastim-pccg

Inactive ingredients: glacial acetic acid, polysorbate 20, sodium hydroxide and sorbitol in Water for Injection.

Manufactured by: Accord BioPharma Inc., 8041 Arco Corporate Drive, Suite 200, Raleigh, NC 27617 USA

U.S. License No.: 2105

Manufactured at: Intas Pharmaceuticals Limited, Plot No. 423/P/A, Sarkhej-Bavla Highway, Moraiya, Ahmedabad, Gujarat 382213, India

For more information, go to www.accordhealthcare.us or call 1-866-941-7875.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Issued: May 2026

Instructions for Use
ENNUMO™ (eh-noo-moe)
(pegfilgrastim-pccg)
injection, for subcutaneous use
Single-Dose Prefilled Syringe

Guide to parts




Figure 1

Important: The needle is covered by the gray needle cap before use.

Important:

Read the Patient Information for important information you need to know about ENNUMO before using these Instructions for Use.

Before you use an ENNUMO prefilled syringe, read this important information.

Storing the prefilled syringe

- Store ENNUMO in the refrigerator between 36°F to 46°F (2°C to 8°C).
- Avoid freezing. If ENNUMO is accidentally frozen, allow the prefilled syringe to thaw in the refrigerator before injecting.
- **Do not** use an ENNUMO prefilled syringe that has been frozen more than 1 time. Throw it away and use a new ENNUMO prefilled syringe.
- Keep the prefilled syringe in the original carton to protect from light or physical damage.
- Take the prefilled syringe out of the refrigerator 30 minutes before use and allow it to reach room temperature, 68°F to 77°F (20°C to 25°C), before preparing an injection.
- Throw away (dispose of) any ENNUMO that has been left at room temperature, 68°F to 77°F (20°C to 25°C), for more than 48 hours.
- Keep the ENNUMO prefilled syringe out of the reach of children.

Using the prefilled syringe

- **It is important that you do not try to give the injection unless you or your caregiver has received training from your healthcare provider.**
- Make sure the name ENNUMO appears on the carton and prefilled syringe label.
- Check the carton and prefilled syringe label to make sure the dose strength is 6 mg.
- You should not inject a dose of ENNUMO to children weighing less than 99 pounds (45 kg) from an ENNUMO prefilled syringe.
- **Do not** use a prefilled syringe after the expiration date on the label.
- **Do not** shake the prefilled syringe.
- **Do not** remove the gray needle cap from the prefilled syringe until you are ready to inject.
- **Do not** use the prefilled syringe if the carton is open or damaged.
- **Do not** use a prefilled syringe if it has been dropped on a hard surface. The prefilled syringe may be broken even if you cannot see the break. Use a new prefilled syringe.
- Avoid touching the needle guard activation clips before use. Touching them may cause the syringe safety guard to be activated too early. **Do not** use the prefilled syringe if the syringe safety guard has been activated. Use another prefilled syringe that has not been activated and is ready to use.
- The gray needle cap on the prefilled syringe contains dry natural rubber (made from latex). **Tell your healthcare provider if you are allergic to latex. You should not give ENNUMO using the prefilled syringe if you have latex allergies.**

Call your healthcare provider if you have any questions.

Step 1: Prepare

A. Remove the prefilled syringe carton from the refrigerator.

Check the expiration date.

Important: Do not use if the expiration date has passed.

Remove the syringe tray from the carton. On a clean, well-lit surface, place the syringe tray at room temperature, 68°F to 77°F (20°C to 25°C), for **30** minutes before you give an injection.

- **Do not** use the prefilled syringe if the carton is damaged.
- **Do not** try to warm the prefilled syringe by using a heat source such as hot water or microwave.
- **Do not** leave the prefilled syringe in direct sunlight.
- **Do not** shake the prefilled syringe.

Open the tray by peeling away the cover. Grab the safety guard to remove the prefilled syringe from the tray (see **Figure 2**).




Figure 2

For safety reasons:

- **Do not** grab the plunger rod.
- **Do not** grab the gray needle cap.

B. Inspect the medicine and prefilled syringe (see **Figure 3**).




Figure 3

Make sure the medicine in the prefilled syringe is clear and colorless. It is normal to see air bubbles in the syringe.

- **Do not** use the prefilled syringe if:
 - The medicine is cloudy or discolored or contains flakes or particles.
 - Any part appears cracked or broken.
 - The prefilled syringe has been dropped.
 - The gray needle cap is missing or not securely attached.
 - The expiration date printed on the label has passed.

In all cases, use a new prefilled syringe and call your healthcare provider.

C. Gather all materials needed for the injection (see **Figure 4**).

Wash your hands thoroughly with soap and water.

On a clean, well-lit work surface, place the:

- Prefilled syringe
- Alcohol wipe
- Cotton ball or gauze pad
- Adhesive bandage
- Sharps disposal container




Figure 4

Step 2: Get ready

D. Prepare and clean the injection site (see **Figure 5**).




Figure 5

You can use:

- Thigh
- Stomach area (abdomen), except for a **2-inch** area right around the navel (belly button)
- Upper outer area of the buttocks (only if someone else is giving you the injection)
- Outer area of upper arm (only if someone else is giving you the injection)

Clean the injection site with an alcohol wipe. Let the skin dry.

- **Do not** touch this area again before injecting.
- If you want to use the same injection site, make sure it is not the same spot on the injection site you used for a previous injection.
- **Do not** inject into areas where the skin is tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks.

E. Hold the prefilled syringe by the syringe barrel. Carefully pull the gray needle cap straight off and away from your body (see **Figure 6**).




Figure 6

- **Do not** remove the gray needle cap from the prefilled syringe until you are ready to inject.
- **Do not** twist or bend the gray needle cap.

- **Do not** hold the prefilled syringe by the plunger rod.
- **Do not** put the gray needle cap back onto the prefilled syringe.

Important: Throw the gray needle cap into the sharps disposal container.

Step 3: Subcutaneous (under the skin) injection

F. Pinch the injection site to create a firm surface (see **Figure 7**).




Figure 7

Important: Keep skin pinched while injecting.

G. Hold the pinch. Insert the needle into the skin at 45 to 90 degrees (see **Figure 8**).




Figure 8

H. Using slow and constant pressure, push the plunger rod until it reaches the bottom (see **Figure 9**).




Figure 9

- I. Keep the plunger fully pressed down while you carefully pull the needle straight out from the injection site (see **Figure 10**).




Figure 10

Important: When you remove the syringe, if it looks like the medicine is still in the syringe barrel, this means you have not received a full dose. Call your healthcare provider right away.

- J. Slowly release the plunger and allow the safety guard to automatically cover the exposed needle (see **Figure 11**).




Figure 11

Step 4: Finish

K. Discard (throw away) the used prefilled syringe (see **Figure 12**).



Figure 12

- Put the used prefilled syringe in an FDA-cleared sharps disposal container right away after use. **Do not** throw away (dispose of) the syringe in the household trash.
- If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
 - made of a heavy-duty plastic,
 - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
 - upright and stable during use,
 - leak-resistant, and
 - properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container.
- There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at:
<http://www.fda.gov/safesharpsdisposal>
- **Do not** reuse the prefilled syringe.
- **Do not** recycle the prefilled syringe or sharps disposal container or throw them into household trash.

Important: Always keep the sharps disposal container out of the reach of children.

L. Examine the injection site.

If there is blood, press a cotton ball or gauze pad on the injection site. **Do not** rub the injection site. Apply an adhesive bandage if needed.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured by:

Accord BioPharma Inc.
8041 Arco Corporate Drive, Suite 200, Raleigh, NC 27617 USA

US License No. 2105

Manufactured at:

Intas Pharmaceuticals Limited
Plot No: 423/P/A, Sarkhej-Bavla Highway, Moraiya,

Ahmedabad, Gujarat 382213, India

Issued: May 2026